Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 24, 2021
Discovery & Translation
New mechanisms and modalities emerge for TIGIT
2021 ASH and SITC abstracts are low on data, high on innovation
BioCentury | Mar 5, 2021
Product Development
March 4 COVID Quick Takes: More guidance on vaccines for variants; plus EMA begins review of Sputnik V, Novartis-CureVac, Bharat-Ocugen, Novavax and more
The ACCESS consortium, a coalition of regulatory authorities from the U.K., Australia, Canada, Singapore and Switzerland, released guidance on Thursday outlining the data needed to approve
BioCentury | May 5, 2016
Distillery Therapeutics
Therapeutics: Tumor necrosis factor ligand superfamily member 14 (TNFSF14; LIGHT; CD258); epidermal growth factor receptor (EGFR); programmed cell death 1 ligan
BioCentury | Mar 18, 2013
Strategy
Japan's biggest biotech
KHK's scientist-CEO expanding beyond Japan with in-house tech, academic targets
Items per page:
1 - 10 of 10